1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof

US10954228B2 · kind B2 · utility

Assignees

• The Trustees of the University of Pennsylvania · US
• THE UAB RESEARCH FOUNDATION · US
• VANDERBILT UNIVERSITY · US
• NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES · US

Inventors

• David J. Maloney · Point of Rocks, US
• Alex G. Waterson · Durham, US
• Ganesha Rai Bantukallu · Falls Church, US
• Kyle Ryan Brimacombe · Bethesda, US
• Plamen P. Christov · Mount Juliet, US
• Chi V. Dang · Penn Valley, US
• Victor Darley-Usmar · Birmingham, US
• Matthew Hall · Deakins Range, US
• Xin Hu · Chestertown, US
• Ajit Jadhav · Chantilly, US
• Somnath Jana · Nashville, US
• Kwangho Kim · Nashville, US
• William J. Moore · Hagerstown, US
• Bryan T. Mott · College Park, US
• Leonard M. Neckers · Bethesda, US
• Anton Simeonov · Rockville, US
• Gary A. Sulikowski · Brentwood, US
• Daniel Jason Urban · Rockville, US
• Shyh-Ming Yang · Doylestown, US

Key dates

• Filing date: Jun 29, 2017
• Grant date: Mar 23, 2021
• Expiry date: Jun 29, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.